Why the study?
Do broad-spectrum anti-inflammatory strategies improve outcomes in patients with heart failure?
Do broad-spectrum anti-inflammatory strategies improve outcomes in patients with heart failure?
This review highlights the shift from targeted anti-cytokine therapies, which failed to show benefit, to broad-spectrum anti-inflammatory modalities in heart failure management.
The understanding of the pathomechanisms leading to heart failure has evolved from the simplistic pump-failure concept to the more complex syndrome involving neurohormonal and inflammatory systems. Anti-inflammatory therapy targeting specific cytokines, however, such as tumor necrosis factor-alpha, has failed to show clinical benefit. As a result, the focus has turned toward more broad-spectrum anti-inflammatory strategies. This review examines the various broad-spectrum anti-inflammatory modalities that have been used in heart failure: IV immunoglobulin administration, immune modulation therapy, immune adsorption, and plasmapheresis.
No takes yet. Share an insight, caveat, or question.
Ramasubbu et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: